Propanc Biopharma, Inc.

PPCB

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001517681

None

No letter

4 of 14 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $12.8M
Warnings	dilution, thin data not computable: short runway, degenerate inputs, distress
Inputs computable	4 of 14
Graded from	filings received through Sep 25, 2026 40 days before the rescan; latest periodic filing 10-K received Sep 25, 2026
Last close	$1.80 2026-11-02; market equity $11.4M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Sep 25, 2026

used in this Annual Report on Form 10-K, references to the "Company," "Propanc," "we," "our," and "us" refer to Propanc Biopharma, Inc. and its consolidated subsidiary, unless otherwise indicated. In addition, references to our "financial statements" are to our consolidated financial statements included elsewhere in this Annual Report on Form prepare our consolidated financial statements in United States dollars and in accordance with generally accepted accounting principles as applied in the United States, ("U.S. GAAP").

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 5.0						
Gross profitability	not computable	32.4%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.3%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

average invested capital must exceed $1,000,000						
Accruals ratio	(81.3%)	(6.6%)	5.0	803	2026-06-30	
Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 0						
Solvency, sleeve percentile 74.0						
Twelve-month failure probability	not computable	0.08%				
latest liabilities, cash plus short-term investments, book equity, and shares are required						
Altman Z double-prime	(40.83)	(0.35)	85.9	747	2026-06-30	
Net debt to EBITDA	not computable	1.82x				
EBITDA must exceed $100,000						
Interest coverage	not computable	(4.51x)				
latest aligned inputs end 2023-06-30; latest annual assets end 2026-06-30						
Current ratio	2.55x	2.92x	62.0	828	2026-06-30	
Growth and financing, sleeve percentile 96.7						
Revenue growth, three-year compound	not computable	10.1%				
four annual observations are required; found 0						
Free cash flow growth, three-year compound	not computable	10.9%				
four consecutive annual FCF observations are required; found 4						
Reinvestment rate	not computable	37.1%				
NOPAT must exceed $100,000						
Asset growth, three years	not computable	2.2%				
current value must be positive and the base must exceed $100,000						
Net share issuance, one year	1,135.9%	2.5%	96.7	632	2026-09-23	

Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 1135.9%
Thin data	4 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-11-02 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(98.4%)	(2.2%)	0
Distance from 52-week high	(94.2%)	(29.8%)	3
EBIT to enterprise value	(168.6%)	(1.5%)	4
Free cash flow yield	(52.5%)	(0.9%)	14
Book value to price	0.87	0.28	83
Sales to price	not computable	0.30	
Composite equity issuance, five years	not computable	20.5%	
Relative strength against the sector, log excess return	(4.31)	(0.19)	0

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2026-06-30	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	n/a
Operating cash flow, four quarters	n/a
Months of runway	not finite
Days since last periodic filing	40 (10-K received Sep 25, 2026)
Median daily dollar volume, 63 sessions	$96,179

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	operating income	us-gaap:OperatingIncomeLoss	-$2.0M	2022-06-30	2023-09-28	10-K	23-034632
2	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$2.7M	2022-06-30	2023-09-28	10-K	23-034632
3	income tax	us-gaap:IncomeTaxExpenseBenefit	-$54,977	2022-06-30	2023-09-28	10-K	23-034632
4	total debt	us-gaap:LongTermDebt	$926,438	2022-06-30	2023-09-28	10-K	23-034632
5	book equity	us-gaap:StockholdersEquity	-$3.0M	2022-06-30	2024-09-30	10-K	24-038815
6	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$4,067	2022-06-30	2022-09-28	10-K	22-027033
7	total debt	us-gaap:LongTermDebt	$624,583	2021-06-30	2022-09-28	10-K	22-027033
8	book equity	us-gaap:StockholdersEquity	-$3.1M	2021-06-30	2023-09-28	10-K	23-034632
9	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$2,255	2021-06-30	2022-09-28	10-K	22-027033
10	net income	us-gaap:NetIncomeLoss	-$18.9M	2026-06-30	2026-09-25	10-K	26-044373
11	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$5.7M	2026-06-30	2026-09-25	10-K	26-044373
12	assets	us-gaap:Assets	$12.8M	2026-06-30	2026-09-25	10-K	26-044373
13	assets	us-gaap:Assets	$19.6M	2025-06-30	2026-09-25	10-K	26-044373
14	current assets	us-gaap:AssetsCurrent	$8.5M	2026-06-30	2026-09-25	10-K	26-044373
15	current liabilities	us-gaap:LiabilitiesCurrent	$3.4M	2026-06-30	2026-09-25	10-K	26-044373
16	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$144.5M	2026-06-30	2026-09-25	10-K	26-044373
17	operating income	us-gaap:OperatingIncomeLoss	-$18.2M	2026-06-30	2026-09-25	10-K	26-044373
18	book equity	us-gaap:StockholdersEquity	$9.4M	2026-06-30	2026-09-25	10-K	26-044373
19	liabilities	us-gaap:Liabilities	$3.4M	2026-06-30	2026-09-25	10-K	26-044373
20	depreciation amortization	us-gaap:Depreciation	$1,993	2022-06-30	2023-09-28	10-K	23-034632
21	operating income	us-gaap:OperatingIncomeLoss	-$1.8M	2023-06-30	2024-09-30	10-K	24-038815
22	interest expense	us-gaap:InterestExpense	$532,821	2023-06-30	2023-09-28	10-K	23-034632
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$2,874	2019-06-30	2020-10-01	10-K	20-018726
24	depreciation amortization	us-gaap:Depreciation	$2,306	2019-06-30	2020-10-01	10-K	20-018726
25	operating income	us-gaap:OperatingIncomeLoss	-$2.6M	2019-06-30	2020-10-01	10-K	20-018726
26	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$5.8M	2019-06-30	2019-10-15	10-K	19-015529
27	income tax	us-gaap:IncomeTaxExpenseBenefit	-$115,437	2019-06-30	2020-10-01	10-K	20-018726
28	current assets	us-gaap:AssetsCurrent	$91,132	2019-06-30	2020-10-01	10-K	20-018726
29	current liabilities	us-gaap:LiabilitiesCurrent	$4.4M	2019-06-30	2020-10-01	10-K	20-018726
30	current assets	us-gaap:AssetsCurrent	$60,890	2018-06-30	2019-10-15	10-K	19-015529
31	current liabilities	us-gaap:LiabilitiesCurrent	$6.8M	2018-06-30	2019-10-15	10-K	19-015529
32	assets	us-gaap:Assets	$72,365	2024-06-30	2025-09-29	10-K	25-016069
33	assets	us-gaap:Assets	$60,328	2023-06-30	2024-09-30	10-K	24-038815
34	shares outstanding	dei:EntityCommonStockSharesOutstanding	6,331,116	2026-09-23	2026-09-25	10-K	26-044373
35	shares outstanding	dei:EntityCommonStockSharesOutstanding	12,806,747	2025-09-24	2025-09-29	10-K	25-016069

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.